RESUMO
Background and Aim: New substances for neoplasm treatment have to be carefully studied to minimize adverse effects and prevent disease progression stimulation. Jatobá is a typical tree of the Cerrado and Caatinga biome, with antifungal, antimicrobial, larvicide, antioxidant, and antiproliferative properties. This study aimed to investigate the action of the crude extract of Jatobá leaves (EBFJ) on canine osteosarcoma (CO) cells and analyze the expression of biomarkers in neoplasm progression. Materials and Methods: D17 cells were cultured and subjected to treatment with EBFJ at different concentrations (10 µg/mL; 100 µg/mL; 1000 µg/mL; 2000 µg/mL; and 5000 µg/mL) and exposure times (24 h, 48 h, and 72 h). The tetrazolium reduction assay and the immunocytochemistry technique, with anti-Bcl2, anti-p53, and anti-Ki-67 antibodies, were used to observe the effect of the extract on cell proliferation. Results: Doses of 2000 µg and 5000 µg had cell viability of 300.80% and 361.84%, respectively. The extract did not show significant cytotoxicity of samples with the control group. The confluence of cells, the number of labeled cells, and the expression of Bcl2, Ki-67, and p53 were higher in the groups treated with EBFJ, with a statistical difference from the group without treatment. Conclusion: EBFJ was not cytotoxic and had a proliferative effect on CO D17 cells. The confluence of cells, the number of labeled cells, and the expression of Bcl2, Ki-67, and p53 were higher in the groups treated with the extract.
RESUMO
RESUMEN Presentamos el caso de una paciente de 67 años con un diagnóstico clínico de reacción adversa cutánea al uso del agente quimioterapéutico citarabina, el cual recibió en el contexto del tratamiento médico por leucemia mieloide aguda. Se realiza la descripción epidemiológica, signos clínicos, evolución médica y realizamos la comparación con casos similares previamente descritos. Para excluir otros diagnósticos diferenciales se realizó estudio histopatológico y su correlación con el examen clínico.
ABSTRACT We report the case of a 67-year-old female patient with a medical diagnosis of cutaneous adverse reaction to the use of the chemotherapeutic agent cytarabine, which she received in the context of medical treatment for acute myeloid leukemia. Epidemiological description, clinical signs, medical evolution, and comparison with similar cases previously described. In order to exclude other differential diagnoses, histopathological study and its correlation with the clinical examination were performed.
RESUMO
Hemorrhagic cystitis is the main adverse effect associated with the clinical use of oxazaphosphorine, resulting in increased oxidative stress and proinflammatory cytokines, which culminate in injury of the bladder tissue. The aim of this study was to evaluate the protective effect of isopropyl gallate (IPG) against ifosfamide (IFOS)-induced hemorrhagic cystitis in mice. The induction of the hemorrhagic cystitis model was carried out using a single dose of IFOS (400 mg/kg, i.p.) four hours after oral pretreatment with IPG (6.25, 12.5, 25, and 50 mg/kg) or saline (vehicle). Mesna (positive control; 80 mg/kg, i.p.) was administered four hours before and eight hours after induction of cystitis. In the present study, IPG 25 mg/kg significantly decreased edema and hemorrhage, with a reduction of the bladder wet weight (36.86%), hemoglobin content (54.55%), and peritoneal vascular permeability (42.94%) in urinary bladders of mice. Interestingly, IPG increased SOD activity (89.27%) and reduced MDA levels (35.53%), as well as displayed anti-inflammatory activity by decreasing TNF-α (88.77%), IL-1ß (62.87%), and C-reactive protein (56.41%) levels. Our findings demonstrate that IPG has a substantial protective role against IFOS-induced hemorrhagic cystitis in mice by enhancing antioxidant activity and proinflammatory mechanisms. Thus, IPG represents a promising co-adjuvant agent in oxazaphosphorine-based chemotherapy treatments.
RESUMO
BACKGROUND: In oncology, pharmacists contribute to safety and effectiveness of drug treatment, identifying, preventing and forwarding solutions to drug-related problems (DRPs). However, it is still necessary to elucidate the profile of drug-related problems in pediatric cancer treatment to contribute to guide clinical pharmacy activities. METHODS: A retrospective cross-sectional study was conducted. Records on Excel® spreadsheets of 2 years of pharmaceutical assistance were analyzed regarding the prescriptions of chemotherapy for hospitalized patients aged 0-19 years. Data on age, sex, cancer diagnosis, protocol and drugs prescribed were collected. Causes and types of DRPs and pharmacists' interventions as their rate of acceptance were measured according to PCNE V 9.0. RESULTS: Drug-related problems were identified for 84 patients, in 5.3% of analyzed prescriptions. Leukemias, patients aged 0-4 years and male sex were associated with higher rates of drug-related problems. The BFM 2009 protocol for acute lymphocytic leukemia treatment had the highest frequency of prescriptions with drug-related problems. Main drug-related problems were related to effectiveness (49.2%) and safety (33.2%), with most of them due to drug selection and dose. Rate of acceptance of interventions was 92.2% and 90.6% of drug-related problems were fully resolved. Mercaptopurine and filgrastim were the drugs most associated with drug-related problems. Oral antineoplastic agents represented 36% of the prescriptions with drug-related problems. CONCLUSION: The high rate of acceptance of pharmacist interventions demonstrates the relevance of the pharmacist participation in the care of hospitalized pediatric patients undergoing chemotherapy. Pharmacists need to take attention to cases of necessity of drug prescription, intervening with other health professionals. Special attention to oral chemotherapy is required.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Serviço de Farmácia Hospitalar , Humanos , Masculino , Criança , Farmacêuticos , Pacientes Internados , Estudos Retrospectivos , Monitoramento de Medicamentos , Estudos Transversais , Serviço de Farmácia Hospitalar/métodosRESUMO
PURPOSE: We investigated whether self-compassion and mindfulness are associated with quality of life in patients undergoing antineoplastic chemotherapy. METHODS: A cross-sectional survey of 183 patients (100% response rate) undergoing chemotherapy was conducted at a Brazilian hospital between August and December 2019. A questionnaire was administered by the research team, collecting clinical and demographic data as well as responses to the Self-compassion scale, Mindful Attention Awareness Scale, and the Functional Assessment of Cancer Therapy-General instrument. Data analysis comprised descriptive and inferential statistics, with multiple regression and Spearman's rank-order correlation testing for associations between quality of life, self-compassion and mindfulness. RESULTS: Mean scores for the study variables were 4.23 (SD = 0.63) for self-compassion, 69.05 (SD = 13.27) for mindfulness, and 80.25 (SD = 12.62) for quality of life. Significant positive correlations were observed between quality of life and self-compassion (r = 0.466, p < 0.001), as well as for quality of life and mindfulness (r = 0.325, p < 0.001). Higher levels of self-compassion and mindfulness were associated with better quality of life. CONCLUSIONS: This research suggests merit in further studies of self-compassion and mindfulness either as predictor variables or for direct causal effect on quality of life in cancer patients undergoing antineoplastic chemotherapy. We recommend that future studies incorporate an intervention and experimental design.
Assuntos
Empatia , Atenção Plena/estatística & dados numéricos , Neoplasias/tratamento farmacológico , Qualidade de Vida/psicologia , Autoimagem , Idoso , Brasil , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e QuestionáriosRESUMO
Plasmocitomas são geralmente incomuns em cães, representando cerca de 3% das neoplasias, e, em gatos, esse número é ainda menor, sendo consideradas raras e observadas em aproximadamente 1% dos casos. Objetiva-se com este trabalho apresentar um relato de caso de uma doença muito pouco relatada na oncologia veterinária, o plasmocitoma extramedular oral em felinos domésticos. A metodologia empregada para a construção deste trabalho deu-se por meio de: consulta a referências bibliográficas; observação e acompanhamento dos processos realizados no âmbito hospitalar, além da consulta ao prontuário médico do paciente. Embora muito descrita na literatura a utilização da cirurgia de mandibulectomia ou maxilectomia na terapia de plasmocitomas orais em cães, são escassos os relatos do emprego da técnica em gatos. Porém, é certo afirmar que a eletroquimioterapia, associada à quimioterapia antineoplásica adjuvante, promoveu uma ótima sobrevida (407 dias), sem comprometimento na qualidade de vida do paciente, mostrando que, mesmo com um tratamento menos invasivo e conservador, foi possível cuidar do paciente de maneira efetiva. Uma grande dificuldade, durante todo o processo, foi a falta de relatos científicos específicos para o plasmocitoma oral em felinos. As neoplasias orais em felinos e, principalmente, as originadas por plasmócitos precisam ser mais estudadas e relatadas, promovendo maior conhecimento técnico e científico a todos os profissionais da área.
Plasmocytomas are generally uncommon in dogs, representing about 3% of neoplasms, and in cats, this number is even lower, being considered rare and observed in approximately 1% of cases. The aim of this work is to present a case report of a disease that is rarely reported in veterinary oncology: oral extramedullary plasmacytoma in domestic cats. The methodology used for the construction of this work was given through: consultation of bibliographic references; observation and monitoring of processes performed in the hospital, in addition to consulting the patient's medical record. Although the use of mandibulectomy or maxillectomy surgery to treat oral plasmacytomas in dogs is widely described in the literature, there are few reports on the use of the technique in cats. However, it is true to say that electrochemotherapy, associated with adjuvant antineoplastic chemotherapy, promoted an excellent survival (407 days), without compromising the patient's quality of life, showing that even with a less invasive and conservative treatment it was possible to care for the patient in a way effective. A major difficulty throughout the process was the lack of specific scientific reports for oral plasmacytoma in felines. Oral neoplasms in felines and mainly those originating from plasmocytes need to be further studied and reported, promoting greater technical and scientific knowledge to all professionals in the field.